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Abstract
Issues. Recovery is a theoretical construct and empirical object of inquiry. The aim was to review whether outcome measures
used in randomised controlled trials of drug treatment reflect a comprehensive conceptualisation of recovery. Approach. System-
atic review using the following databases: Cochrane Database of Systematic Reviews, Cochrane Controlled Register of Trials,
Database of Abstracts of Reviews of Effect, Web of Science, MEDLINE, Embase and PsycINFO. Search returned 6556
original articles and 504 met the following inclusion criteria: randomised controlled trial in English-language peer-reviewed
journal; sample meets criteria for drug dependence or drug use disorder; reports non-substance use treatment outcomes. Review
protocol registration: PROSPERO (CRD42018090064). Key Findings. 3.8% of the included studies had a follow up of
2 years or more. Withdrawal/craving was present in 31.1% of short-term versus 0% of long-term studies. Social functioning
in 8% of short-term versus 36.8% of long-term studies. Role functioning (0.9 vs. 26.3%), risk behaviour (15.6 vs. 36.8%)
and criminality (3.8 vs. 21.1%) followed a similar pattern. Housing was not examined short-term and unregularly long-term
(2.0%). ‘Use of health-care facilities’, clinical psychological, behavioural factors were frequently reported. Physiological or
somatic health (15.2 vs. 10.5%), motivation (14.2 vs. 15.8%) and quality of life (7.1 vs. 0%) were less frequently reported.
Conclusion. The short time interval of the follow up and lack of information on relevant factors in recovery prevents the
development of evidence-based approaches to improve these factors. Particularly, measures of social and role functioning should
be added to reflect an adequate conceptualisation of recovery. [Bjornestad J, McKay JR, Berg H, Moltu C, Nesvåg S.
How often are outcomes other than change in substance use measured? A systematic review of outcome measures
in contemporary randomised controlled trials. Drug Alcohol Rev 2020;39:394–414]
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Introduction
There is little consensus on the conceptualisation of
long-term recovery in the drug use disorder (DUD)
use literature. Recovery operationalisations influence
treatment research, inform clinical practice and deter-
mine the efficacy or effectiveness of treatments and
interventions. Thus, these operationalisations need to be
valid to understand what is and what is not high-quality
care. In severe mental illness, the operationalisation of
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recovery is more developed than in DUD [1]. Concrete
operationalisation suggestions have been made
(e.g. personal and clinical recovery), including functional
and social aspects central to recovery in severe mental ill-
ness [2–4]. While specific factors, such as reduction in
criminality, are more prominent in DUD recovery than
in recovery from severe mental illness, general core fac-
tors, including an increase in community and social
functioning, are common to these conditions [5–9].
The same applies for the reduction in core symptoms,
for example substance use and severe psychiatric
symptoms, as essential for achieving stable long-term
recovery [10–12]. In this systematic review, we pro-
pose that conceptualisations of recovery from severe
mental illness are applicable in DUD. Second, we
systematically review to what extent substance use
outcome measures used in randomised controlled tri-
als (RCT) of drug treatment reflect a comprehensive
understanding of recovery.
Clinical recovery traditionally refers to mental illness
or DUD as distinct disorders displaying core symptoms.
Clinical recovery is achieved when the core symptoms
subside below diagnostic thresholds. Furthermore, the
criteria for clinical recovery are based on researcher-
derived thresholds and predefined objectives, including
symptoms and functioning. Recovery also has a tempo-
ral criterion intended to indicate the stability of the
recovery [4,13,14]. While subject to ongoing debate, a
minimum duration of 2 years has been proposed. Two
years allows for the possibility of new habits and behav-
iours to take hold, a relapse may have occurred or not,
the maintenance of a drug-free social network has
begun to consolidate, etc. [15–17]. There is more wide-
spread agreement on symptom criteria for changes in
drug use (i.e. use to abstinence or moderation) in the
DUD literature [18,19]. However, consensus is lacking
regarding criteria for functional and social recovery.
Because of the extensive identity changes that are often
considered necessary to handle a drug-free life, or even
drug moderation, some have set a 5-year temporal crite-
rion for DUD recovery [20–23].
The personal recovery tradition arose as a reaction to
researcher-derived recovery criteria. Personal recovery
is conceptualised beyond core symptom reduction as:
‘…a process of restoring ameaningful sense of belonging
to one’s community and positive sense of identity apart
from one’s condition while rebuilding a life despite or
within the limitations imposed by that condition’
[24,25]. Synthesising the research on personal recovery
into an empirically based concept, Leamy et al. [26] out-
lined the Connectedness, Hope & Optimism, Identity,
Meaning and Empowerment framework, in which five
main long-term processes characterise recovery:
(i) connectedness; (ii) hope and optimism; (iii) identity;
(iv) meaning in life; and (v) empowerment. Empirical
research suggests that these processes are relevant for
DUD recovery [6,12,21,22].
The relational recovery tradition critiques the clinical
and personal recovery approaches for not incorporating
the interpersonal embeddedness of recovery [27]. This
framework sees interpersonal contexts as permeating
individualistic or subjective concepts like connectedness
and self-agency [28], and advocates against con-
ceptualising recovery as separate from the social and
relational reality that partly defines the potentialities
for each individual. These issues are just as relevant
for DUD as for serious mental illness [29,30].
Though there are differences between these three
approaches, the perspectives of clinical, personal and
relational recovery share common ground [30]. Consis-
tent with empirical findings, symptom reduction is seen
as a necessary but insufficient requirement to maintain
recovery over time. Although clinical recovery is unique
in its definition of a concrete temporal criterion [15,16],
recovery is universally described as a non-linear and
cumbersome long-term growth process, with the threat
of relapse often present. It is also acknowledged that a
good outcome sometimes requires a long-term care
effort [11–13,31]. Empirical support for these findings is
solid and consistent across different clinical disciplines
and research traditions [10,17,22,32–35]. On this basis,
it is proposed that treatment outcome research in DUD
should reflect these findings when assessing recovery.
The aim of this review was to systematically review
and identify non-substance use (non-SU) treatment
outcome measures used in RCTs on illicit drug use
over the last 10 years, and to assess the degree to
which they reflect any of the above-mentioned perspec-
tives of recovery. RCTs were chosen because this
methodology is generally considered the most valuable
for both evaluating treatment efficacy and effectiveness
and developing treatment guidelines.
Methods
This review followed the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA)
guidelines [36] to ensure comprehensive and transparent
reporting of procedures and results. The protocol was
registered in the International Prospective Register of
Systematic Reviews (PROSPERO) in March 2018 (reg-
istration number: CRD42018090064) (Appendix 1).
Search strategy
Two independent researchers (JB and SN) conducted
a search of the literature using the following electronic
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databases: Cochrane Database of Systematic Reviews,
Cochrane Central Register of Controlled Trials, Data-
base of Abstracts of Reviews of Effect, Web of Science,
MEDLINE, Embase and PsycINFO. Variations and
combinations of terms targeting five main concepts were
used in the search: RCTs, substance abuse, substances,
therapeutic approaches and recovery success. Subject
headings belonging to the individual databases
(e.g. MeSH subject terms) and free-text terms (see
Appendix 2 for model search) were also used. The sea-
rch queries were reviewed by an information scientist. In
addition, a hand search was performed using reference
lists from reviews and meta-analyses identified in the
main search. In cases of doubt, the full-text paper was
read to determine eligibility. Papers published between
January 2008 and January 2019 were included. The last
search was conducted on 11 January 2019.
Eligibility criteria
The included articles met the following criteria:
• Empirical study published in English-language peer-
reviewed journal.
• Study sample meets the criteria for dependence syn-
drome (International Classification of Diseases, 10th
revision) or moderate–severe DUD (Diagnostic and
Statistical Manual of Mental Disorders, Fifth Edition).
• Randomised controlled trial.
• Reports non-SU treatment outcomes in addition
to changes in substance use (e.g. social functioning,
employment/school status, criminality, psychological
symptoms).
• Empirical study from the past decade (2008–),
as the recovery field has gained a more solid theoret-
ical and empirical foundation during this time
[1,4,11,26,27,35–37].
Exclusion criteria
Articles were excluded if the study sample was only or
predominantly comprised of individuals with alcohol
dependence, or if the study did not include non-
substance use outcomes.
Data collection
All potential studies were exported into a reference cita-
tion manager (EndNote) before removing duplicates.
Two independent reviewers (authors JB and SN) sepa-
rately performed the screening of titles and abstracts, full-
text analysis and selection of non-SU treatment outcome
measures. Outcome categories (as presented in Tables 1–
3) were developed during 13 consensus meetings
(≈60 min each, JB and SN) and existing taxonomies as
given below. Disagreements were resolved through dis-
cussion until consensus was reached. A third reviewer
(JRM) was available to resolve disagreements and provide
critical evaluation.
Analytic methods and data extraction procedure
A narrative descriptive synthesis was performed for the
included articles. The qualitative synthesis was used to
determine the taxonomy of non-SU outcomes. We
used the suggested taxonomies of Dodd et al. [71],
Bray et al. [72] and Shorter et al [73] as our basis for the
synthesis. Dodd et al. was chosen as their standardisation
includes flexible categories, applicable for general
dimensions that emerge across conditions, such as
functioning [71]. Bray et al. [72] and Shorter et al.
[73] were used to adapt the categorisation specifi-
cally to DUD. Where we could not find normative
taxonomies covering outcomes satisfactory, or we
assessed factors as particularly relevant and specific
for DUD (e.g. criminality), we used the study
authors’ outcome operationalisations as a compass
for developing categories. In this context the follow-
ing data extraction procedure was used: first, non-SU
treatment outcome measures across different domains
(e.g. work, community functioning, social functioning,
health behaviour) were identified. Second, the proper-
ties of each outcome measure were analysed and cat-
egorised based on similarity (e.g. hepatitis C and HIV
related to risky sexual behaviour were both organised
under the ‘Risk behaviour’ tab in Table 1).
Contemporary recovery perspectives address issues of
functioning (e.g. community and social), incorporate
various perspectives on outcome (e.g. service user and
researcher perspectives) and are explicit that a long-
term perspective is crucial particularly with regards to
functional recovery [11,12,29,30]. Since research on
recovery has been growing over the past 10 years, this
became a central rationale for the time limitation in our
search—to test whether the DUD field had incorpo-
rated this shift in focus, from symptom relief (typically
some measure of change in substance use), to more
explicitly addressing function and social factors as
important outcome measures.
For the same reasons, the second part of the synthesis
was a pre-planned sub-analysis to identify long-term
studies using non-substance use outcomes. Here, cut-
off was set to studies with a follow up of at least 2 years,
following Lieberman’s criteria of stable recovery [2].
Also, the temporal criterion was set to 2 years, as this is
suggested as the temporal requirement for recovery in
396 J. Bjornestad et al.
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the clinical recovery literature [15,17]. Acknowledging
the debate in this area, and some researchers advocating
a temporal criterion up to 5 years [20–23], our 2-year
criteria can primarily be viewed as a practical tool and
as a minimum criterion to identify long-term studies.
Finally, descriptive statistics were generated, aimed at




The electronic search returned 6556 articles. After dupli-
cates were removed, 4545 articles remained. A hand sea-
rch of reference lists from reviews and meta-analyses
returned a further 21 articles. Full-text evaluation was
conducted for 761 articles, of which 504 met the inclu-
sion criteria and were included in the final synthesis.
Details of the search results are summarised in Figure 1.
Since the number of screened and included articles was
extensive, it was necessary to develop superordinate cate-
gories (e.g. social functioning). Seven non-SU outcome
categories and seven sub-categories were developed.
Non-SU outcome measures
Details of the included non-SU outcomes are summarised
in Table 1 (see Appendix 3 for substance use measures
used in the included articles). The five most frequently
included outcomeswere: clinical factors (from the category
psychological/behavioural factors) (n = 196); use of health-
care facilities (from the category functioning) (n = 179);
risk behaviour (n = 104); physiological/clinical (somatic)
(n = 103); and withdrawal/cravings (from the category
adverse effects) (n = 93). The five least frequently included
outcomes were: housing (n = 11); role functioning (from
the category functioning) (n = 28); criminality (n = 40);
global functioning—mostly community-related function-
ing (from the category functioning) (n= 51); and quality of
life (from the category functioning) (n = 51). In compari-
son, all studies had at least one DUDmeasure, which was
also almost always reported as an outcome. Substance use
outcome measures were spread across 22 different sub-
categories (e.g. days of drug use last month, substance use
problems past 90 days, illicit opiate use).
Follow-up duration
From the included 504 research studies, 42.1% had less
than 13 weeks of follow up, 29.6% had between 13 and
26 weeks, 21.8% had between 27 and 52 weeks, 2.8%
had between 53 and 103 weeks and 3.8% had at least
2 years of follow up. The longest follow up was
416 weeks.
Relation between length of follow up and non-SU outcomes
included
The most evident differences in non-SU outcome
inclusions emerged between studies with less than
13 weeks of follow up and studies with at least 2 years
of follow up (see Table 1). A measure of withdrawal/
craving was present in 31.1% of the short-term versus
0% of the long-term studies. A reverse pattern was
demonstrated with measures of social functioning,
which were present in 8% of the short-term studies
versus 36.8% of the long-term studies. Measures of
role functioning (0.9 vs. 26.3%), risk behaviour (15.6
vs. 36.8%) and criminality (3.8 vs. 21.1%) followed a
similar pattern. Housing was not examined in studies
with short-term follow up, and only examined in one
with long-term follow up (5.3%). ‘Use of health-care
facilities’ was frequently reported across follow-up
duration categories. Here, however, the greatest differ-
ence was again between follow ups of less than
13 weeks and greater than 1 year (26.9 vs. 52.6%).
Clinical psychological and behavioural factors were
generally frequently reported (41.0 vs. 31.6%). Physio-
logical or clinical (somatic) health (15.2 vs. 10.5%),
motivation (14.2 vs. 15.8%) and quality of life (7.1
vs. 0%) showed similar patterns, but with substantially
lower percentages. More studies with only one out-
come in addition to change in substance use were
found between 2014 and 2019 (55.1%) than 2008 and
2013 (41.2%).
Long-term interventions and reported effects on DUD and
non-SU outcomes
Table 2 displays details on studies with follow ups of
between 1 and 2 years, and Table 3 presents details on
studies with at least 2 years of follow up. Reported treat-
ment effects are also presented. Slightly over two-thirds
(69.7%) of the studies evaluated what may be termed
complex interventions, which were primarily treatment
programs with multiple components or several treat-
ments/treatment elements merged together. Conversely,
slightly less than one-third (30.3%) of the studies evalu-
ated more narrowly focused interventions, usually single
treatments such as cognitive behavioural therapy or
targeted HIV-prevention programs. Ten percent of the
studies showed a positive effect on DUD outcomes but
no effect on non-SU outcomes. Conversely, 6.7% had a
398 J. Bjornestad et al.
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positive effect on non-SU outcomes but no effect on
DUD outcomes. In total, 57.6% of the studies showed a
significant positive effect on at least one of the non-SU
outcomes examined during the intervention period
and/or during follow up. Slightly more than half of the
studies (54.6%) had at least one significant positive
effect on DUD outcome, and 42.4% had a significant
positive effect on at least one non-SU outcome and at
least one DUD outcome, indicating a more general pos-
itive recovery effect.
Discussion
New agendas for contemporary recovery research
This review reveals that only a limited number of RCTs
have been conducted using non-SU factors as treatment
outcomes over time. Only 19 of the 504 included stud-
ies (3.8%) had follow ups of at least 2 years. Of these,
11 studies (2.2%) had follow ups of longer than 2 years.
Given the suggested temporal criterion of a minimum
of 2 years’ follow up for recovery, this finding alone sug-
gests that the substance use RCT treatment literature
from the past decade only reflects the above-mentioned
perspectives of clinical, personal and relational recovery
to a very limited degree [1,26,27,31]. Focus on func-
tional and social recovery are prominent in all these per-
spectives. Functional and social recovery are non-linear
and cumbersome processes that usually require more
time than that required to achieve abstinence [11–13,31].
The threat of relapse may continue for years following
the achievement of abstinence [5–9]. Hence, contempo-
rary substance use RCT research may omit important
social recovery factors and processes, including loneli-
ness, social alienation and the pursuit for citizenship
[2,8,29,30]. When poorly handled, these factors are
related to poor course development and relapse. Con-
versely, when overcome, they facilitate personal growth,
perceived agency and social inclusion, possibly making
the hard work of recovery attractive and seen as a realistic
life solution over time [12]. Further, the ways in which
people strengthen and maintain functional outcomes over
time, such as increased school participation or more fre-
quent social meetings [20,21,26], are difficult to under-
stand, given the current evidence base. This requires a
longitudinal study design and focused mediation ana-
lyses, which are usually beyond the scope of most RCTs.
Figure 1. Flow diagram of the reviewing process according to PRISMA. RCT, randomised controlled trial; SU, substance use.
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These limitations make it challenging for clinicians to
work from an evidence base in their attempts to tailor
phase-specific DUD treatment strategies for long-term
recovery efforts.
In line with contemporary recovery research, the 3.8%
of studies with a follow up of at least 2 years are more
likely to report general health and recovery effects than
studies with shorter follow ups. However, one limitation
of these 19 studies is that they typically report the non-
SU outcomes of psychological health (typically reduction
in depression) and use of health-care facilities (typically
treatment retention), but do not report on other non-
SU outcomes. Only seven studies (1.4%) reported
social functioning outcomes, five (1.0%) on role func-
tioning, four (0.8%) on criminality, two (0.4%) on
global functioning and zero studies on quality of life.
The severely limited number of studies measuring these
factors stands in contrast to the fact that they have con-
sistently been associated with good and stable DUD
outcomes in the recovery literature [10–12,31,74,75].
Moreover, conclusions that cut across different recovery
traditions around what constitutes recovery—for exam-
ple long-term increase in community and social func-
tioning, along with reductions in or elimination of
substance use [4,26,27]—are largely ignored. Likewise,
the increasing trend of studies using only one non-SU
outcome in addition to change in substance use (41.2%
between 2008 and 2013 vs. 55.1% between 2014 and
2019) represents a step away from the longitudinal and
multi-dimensional study approach required to investi-
gate long-term recovery.
Limitations
The strengths of the study are evident in its protocol’s
public availability before the review was conducted (via
PROSPERO); this ensured transparency and that the
review was conducted according to PRISMA guide-
lines [36].
One limitation concerns the fact that no advanced
statistical tests were used to assess the reliability and
validity of the reported findings of the included studies.
The scope of the paper was to evaluate outcome mea-
sures and not treatment efficacy, per se. Another limita-
tion is that each individual study was not assessed for
key sources of biases (e.g. sample characteristics). In
addition, and in line with previous research, some stud-
ies were based on small samples, and most instruments
were constructed and tested within Anglo-American
cultures. This typically increases the risk of reporting
bias, suggesting that the included studies represent
selective research dissemination. However, it should be
emphasised that the aim was to identify outcomes with
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was conducted within several literature databases. The
included studies did use samples with somewhat differ-
ent characteristics (e.g. sex, age and level of symptom-
atology), which may violate the transitivity assumption
and thus raises questions regarding the validity of direct
comparisons across the included studies.
Suggested research directions
To improve the scientific knowledge base of treatment
outcomes in DUD it will be advisable to incorporate
functional and social outcomes into longitudinal
research designs more consistently. These outcomes
are already actively used by other initiatives, such as the
Treatment Episode Dataset discharge data [76].
Empirical studies indicate that future research should
focus on detailing the specific effects of social and com-
munity functioning in recovery. For example, we need
to know more about which treatment interventions
bring about sustained improvements in these areas, and
which post-treatment factors mediate improvements in
social and community functioning. In addition, a more
valid temporal criterion that would enable professionals
to more accurately identify vulnerable phases in recov-
ery would be useful for tailoring treatment efforts
towards expected fluctuations in relapse. A broad
investigation should also aim to overcome specific limi-
tations inherent in the RCT study designs, including
sensitivity to contextual factors and comparison of sin-
gle, common clinical metric across different study con-
texts. As suggested by Donovan et al. [77], applying
within-study comparisons may be a more valid alterna-
tive to studying complex phenomena, such as recovery
in DUD. Furthermore, systematic inclusion of service-
user perspectives could prove a viable route to meet this
aim [78]. By asking individuals with first-hand experi-
ence and those outside of the traditional scientific com-
munity for input in the research design, the risk of
implementing measures with low ecological validity is
considerably reduced [79]. In practical terms, the
application of a mixed research design, combining
exploration, hypothesis development and further large-
scale testing (RCTs), could be a feasible solution.
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APPENDIX 1. DEVIATIONS FROM THE
STUDY PROTOCOL
1. Change in research question: Our research question
in the protocol registration (PROSPERO) was the
following: To review the existing literature (RCTs) on
treatment efficacy, and to determine the treatment fac-
tors important for long-term drug reduction and func-
tional recovery after substance abuse. Our research
question in the submitted review was the following:
To systematically review non-SU treatment outcome
measures used in longitudinal randomised controlled tri-
als over the last 10 years, and to assess the degree to
which they reflect any of the above-mentioned perspec-
tives of recovery. RCTs were chosen because this meth-
odology is generally considered the most valuable for
both evaluating treatment efficacy and developing treat-
ment guidelines. The reason for this change: Early in
the review process (after PROSPERO registration)
we did our first search, using our previous aim
(broader criteria, including no time restriction etc.)
as guidance. This search identified an insurmount-
able number of articles and needed to be narrowed.
Also, we identified Tiffany et al. from 2012 (see ref-
erence list), explicitly addressing issues similar to
the aim of our review. However, their findings were
a result of an expert consensus meeting and not a
systematic review of the literature. We knew that
functioning and social functioning had previously
been addressed more prominently in the earlier
DUD literature (e.g. in the 1970s). At this point we
discussed possible approaches that could provide
meaningful and clinically relevant contextualisation
for our review. Here, the idea of different recovery
perspectives (personal, clinical, relational) emerged
as a viable contextualisation, as modern recovery
perspectives both address issues of functioning
(e.g. community and social), incorporate various
perspectives on outcome (e.g. service user and
researcher perspectives) and are explicit that a long-
term perspective is crucial particularly with regards
to functional recovery. Since research on recovery
has been in particular growth over the past 10 years,
this became a central reason for the time limitation
in our search—to test whether the DUD field had
incorporated this shift in focus, from symptom relief
(typically some measure of change in substance
use), to more explicitly addressing function and
social factors as important outcome measures.
2. Extended the study inclusion period to January 2019.
3. Some minor changes in search setup, including eli-
gibility criteria, title search (see model search).
4. Removed the kappa coefficient to assess the level of
agreement of the two independent reviewers for the
selection of included and excluded measures. Due
to the heterogeneity of the data material it was
assessed that the best approach to reach valid out-
come categories was a continuous collaboration
(consensus meetings on a weekly basis).
5. Exclusion criteria: Studies that measured change in
substance use only.
APPENDIX 2. MEDLINE SEARCH FOR
REPLICATION
Database: Ovid MEDLINE(R) Epub Ahead of Print,
In-Process & Other Non-Indexed Citations, Ovid
MEDLINE(R) Daily and Ovid MEDLINE(R) <1946
to Present>.
1. substance-related disorders/ or amphetamine-
related disorders/ or cocaine-related disorders/ or
heroin dependence/ or inhalant abuse/ or mari-
juana abuse/ or opioid-related disorders/ or mor-
phine dependence/ or opium dependence/ or
phencyclidine abuse/ or psychoses, substance-
induced/ or substance abuse, intravenous/ or sub-
stance abuse, oral/ or narcotics/.
2. ((heroin or marijuana or marihuana or hashish or
cannabis* or amphetamine* or opioid* or cocaine
or opiate* or opium* or morphine* or ecstacy or
metaamphetamine or polydrug* or polysubstance*
or multidrug* or solvent* or inhalant* or narcotic*)
adj2 (abus* or misus* or addict* or dependen* or
‘use’ or usage or disorder*)).hw,kf,ti,ab.
3. ((drug* or substance*) adj2 (abus* or misus* or
addict* or dependen* or disorder*)).kf,ti,ab.
4. (sniff* or designer drug* or narcotism).hw,kf,ti,ab.
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5. addiction.hw,kf,ti.
6. 1 or 2 or 3 or 4 or 5
7. therapeutics/ or drug therapy/ or rehabilitation/ or
psychotherapy/.
8. (treatment* or intervention* or rehabilitation or
inpatient* or outpatient* or hospitali?ed. patient*
or residential or day hospital or partial hospital or
continuing care or ‘contin* of Care’ or CBT or
community reinforcement or motivational inter-
viewing or motivational enhancement therapy or
incentives or family therapy or couples therapy or
methadone or suboxone or buprenorphine or thera-
peutic community or medication* or mentali?ation*
or dialectic* or emotion* focused or ‘action and
commitment*’ or psychodynamic* or psychoanaly*
or behavio?r* modification* or behavio?r* therapy or
‘drug adj2 therapy’ or pharmacotherapy).hw,kf,ti.
9. ((‘12’ or twelve) adj (step facilitation or step
program*)).hw,kf,ti.
10. 7 or 8 or 9.
11. (recovery or autorecovery or remission* or auto-
remission* or abstinen* or abstain* or drug free or
sobriety or (life adj2 satisfaction) or wellbeing or
well being or self-quit* or self-change* or self-
agen* or self-restrain* or change strateg* or life*
change* or ‘readiness to change’ or ‘stages of
change’ or ‘quality of life’).hw,kf,ti.
12. ((increas* adj2 function*) or (improv* adj2
function*)).hw,kf,ti,ab.
13. ((reduc* or modif* or decreas*) adj2 (abus* or
misus* or addict* or dependen*)).hw,kf,ti,ab.
14. ‘Quality of Life’/.
15. (vocation* or occupation* or job or jobs or work
or employe* or employment or education* or edu-
cating or school).hw,kf,ti.
16. (social adj2 interact*).kf,ti.
17. life change events/.
18. (life style* adj2 change*).hw,kf,ti.
19. Interpersonal Relations/.
20. 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19.
21. randomized controlled trial.pt.
22. rct*.ti,ab.
23. (randomi?ed. and controlled and trial*).ti,ab.
24. 21 or 22 or 23 (585927).
25. exp. animals/ not humans.sh. (4474870).
26. 24 not 25 (573722).
27. 6 and 10 and 20 and 26 (1065).
28. limit 27 to english language (1052).
29. limit 28 to journal article (1050).
30. remove duplicates from 29 (1030).
Note: RCT filter based on Therapy, category specific/
narrow here: https://www.ncbi.nlm.nih.gov/books/
NBK3827/#pubmedhelp.Clinical_Queries_Filters
APPENDIX 3. DRUG USE SUB-CATEGORIES
• Days of drug use last month
• Substance use problem severity
• Substance use problem severity past month
• Monthly frequency of cannabis use
• Monthly frequency of alcohol use
• Monthly frequency of other drug use
• Substance problems past month
• Substance use problems past 90 days
• Number of days of substance use
• Number of days cocaine use
• Drug use during study period
• One-month abstinence
• Days abstinent during 90-days time period
• Illicit opiate use
• Days of heroin use
• Maximum days of consecutive heroin abstinence
• Drug cessation
• Dependence
• Change in substance use context
• Relapse
• Days to first relapse
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